The Global Access Strategy and Pricing (GASP) Precision Medicine & Lung Cancer Director role directly impacts the ability to achieve business objectives by supporting the development of strategic guidance on access, pricing, optimal reimbursement, launch sequencing, patient value, and evidence generation for the Precision Medicine & Lung Cancer franchise. The Precision Medicine & Lung Cancer franchise is one of the prioritized Oncology franchises and consists of products recently post-DP3, with pre-DP3 indications, and pre-launch and in-line products. The franchise includes the following products: Braftovi, Mektovi, Lorbrena, Xalkori, Sigvotatug Vedotin, and Fetrastobart Vedotin. The objective for the franchise strategy is to advance the treatment of lung cancer through next-generation backbones of treatment and novel combinations from our internal portfolio and with external combination partners. This position will function with a ‘One Global Access and Value’ mindset and work in an aligned manner with the Lung GASP team, HV&E, USMA and Country Access & Value colleagues. The role will be focused on the global launch of Sigvotatug Vedotin and Fetrastobart Vedotin. This person will support the advancement of the integrated value and access strategy (IVAS) in partnership with the cross functional team and aligned to the brand strategy. The IVAS will optimize the long-term value of the products by optimizing the pricing & access strategy including indication launch sequencing and evidence generation plans.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director